Details of the Drug

General Information of Drug (ID: DMDTC7R)

Drug Name
Phenindamine
Synonyms
Fenindamina; Phenindaminum; Phenindiamine; Thephorin; NU 1504; Fenindamina [INN-Spanish]; Nolahist (TN); Phenindamine (INN); Phenindamine [INN:BAN]; Phenindaminum [INN-Latin]; Thephorin (TN); 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno-(2,1-c)pyridine; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Common cold CA00 Approved [2]
Urticaria EB00-EB05 Approved [1]
Vasomotor/allergic rhinitis CA08 Approved [1]
Pruritus EC90 Investigative [3]
Therapeutic Class
Antihistamines
Affected Organisms
Humans and other mammals
ATC Code
R06AX04: Phenindamine
R06AX: Other antihistamines for systemic use
R06A: ANTIHISTAMINES FOR SYSTEMIC USE
R06: ANTIHISTAMINES FOR SYSTEMIC USE
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 261.399
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 1
Chemical Identifiers
Formula
C19H19N
IUPAC Name
2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
Canonical SMILES
CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4
InChI
InChI=1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3
InChIKey
ISFHAYSTHMVOJR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
11291
ChEBI ID
CHEMBL8065
CAS Number
82-88-2
UNII
772BQ8KSST
DrugBank ID
DB01619
TTD ID
D06UDO
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Phenindamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Phenindamine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [5]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Phenindamine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [5]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Phenindamine and Cariprazine. Bipolar disorder [6A60] [6]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Phenindamine when combined with Acetylcholine. Cataract [9B10] [7]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Phenindamine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [8]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Phenindamine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [8]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Phenindamine and OPC-34712. Depression [6A70-6A7Z] [6]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Phenindamine and Esketamine. Depression [6A70-6A7Z] [9]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Phenindamine and Belladonna. Infectious gastroenteritis/colitis [1A40] [6]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Phenindamine and ITI-007. Insomnia [7A00-7A0Z] [6]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Phenindamine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [10]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Phenindamine and Lasmiditan. Migraine [8A80] [11]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Phenindamine and Flibanserin. Mood disorder [6A60-6E23] [12]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Phenindamine and Methylscopolamine. Peptic ulcer [DA61] [6]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Phenindamine and Iloperidone. Schizophrenia [6A20] [6]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Phenindamine and Thiothixene. Schizophrenia [6A20] [6]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Phenindamine and Asenapine. Schizophrenia [6A20] [6]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Phenindamine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [5]
⏷ Show the Full List of 18 DDI Information of This Drug

References

1 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2 Drug information of Phenindamine, 2008. eduDrugs.
3 An evaluation of thephorin as an adjunct in the treatment of pruritic dermatoses. N C Med J. 1949 Sep;10(9):476-9.
4 The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60.
5 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
6 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
7 Multum Information Services, Inc. Expert Review Panel.
8 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
9 Cerner Multum, Inc. "Australian Product Information.".
10 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
11 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
12 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.